WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.
Dr. May Ching Soh highlighted practical approaches when caring for pregnant patients with rheumatic disease.
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…
“I circled 30 minutes … but it feels more like five hours getting ready for work Monday to Friday and only 15 minutes in a hot bath on weekends,” my patient relayed to me. Greg (name changed, obviously) is an ambitious young professional who has axial spondyloarthritis. He’s also a really funny guy with a…
What Are the Therapeutic Alternatives When a Janus Kinase Inhibitor Fails to Work? SAN DIEGO—Treatment alternatives after Janus kinase (JAK) inhibitor failure in real-life conditions were analyzed and presented at ACR Convergence 2023 by Pablo Francisco Muñoz Martínez, a rheumatologist at the Hospital Universitario y Politécnico La Fe, Sagunto, Spain.1 JAK inhibitors are newer, targeted…
SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.
This session (12S114) at ACR Convergence 2023 will review the diagnostic approach to nonradiographic axial spondyloarthritis, with an emphasis on the role of imaging and recognition of its mimics. For your review—or a preview if you plan to catch the session on demand—our article will capture the highlights from Lianne Gensler, MD, Mark Hwang, MD,…